Blog
RSS FeedPosted by Michael Wonder on 23 May 2024
Setmelanotide acetate for the treatment of patients with obesity and hyperphagia in Bardet-Biedl syndrome (final guidance)
22 May 2024 - NICE has published final evidence-based recommendations on the use of setmelanotide acetate (Imcivree) for treating obesity ...
Posted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jul 2022
Novartis’ Beovu recommended by NICE
28 July 2022 - Patients set to benefit from new treatment for sight-threatening eye condition ...
Posted by Michael Wonder on 09 Sep 2021
Professor Gillian Leng to retire from NICE
9 September 2021 - Professor Leng has spent more than 20 years working at NICE. ...
Posted by Michael Wonder on 28 Apr 2021
NICE signs up to join the GetReal Institute
28 April 2021 -NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence ...
Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary ...
Posted by Michael Wonder on 02 Nov 2020
NICE talking to you: trends in early HTA engagement
29 October 2020 - In 2009, NICE was one of the first health technology assessment agencies to offer the opportunity ...
Posted by Michael Wonder on 19 Aug 2020
Keeping pace with pharmaceutical innovation: the importance of the NICE methods review
19 August 2020 - The NICE plays a vitally important role in ensuring patients get timely access to new medicines ...
Posted by Michael Wonder on 17 Aug 2020
NICE publishes guidance on Astellas' Xospata
17 August 2020 - The National Institute for Health and Care Excellence has now published final guidance backing NHS use ...
Posted by Michael Wonder on 10 Oct 2019
Elmiron bags draft NICE approval
10 October 2019 - NICE has published a draft final appraisal regarding Elmiron (pentosan polysulfate sodium) for bladder pain syndrome. ...
Posted by Michael Wonder on 02 Oct 2019
Advancing patient engagement
2 October 2019 - It’s widely accepted that seeking patient input into their health and care improves outcomes for them and ...
Posted by Michael Wonder on 18 Jun 2019
NICE to co-host 2021 HTAi Annual Meeting in Manchester
18 June 2019 - Health Technology Assessment International (HTAi) has announced that NICE has been chosen as co-hosts of their 2021 ...
Posted by Michael Wonder on 02 Apr 2019
NICE nod for breast cancer delay drug
2 April 2019 - NICE has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for ...
Posted by Michael Wonder on 14 Jun 2018
Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions
13 June 2018 - The pathway for bringing a new medicine to the market is dependent on two sequential processes: achieving ...
Posted by Michael Wonder on 16 May 2018
Patient empowerment in Europe: is no further research needed?
15 May 2018 - In economic theory, health care can be considered a clear example of ‘market failure’ caused by ...